---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-035514"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:48:34.627852+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Genprex granted US patent for REQORSA plus PD-L1 antibody combo through 2037

## Summary
- USPTO patent covers REQORSA gene therapy combined with PD-L1 antibodies like Tecentriq, securing exclusivity to 2037.
- Patents now granted in US and Korea; applications pending in Europe, Canada, Brazil, China, Israel.
- Acclaim-3 Phase 1/2 trial for ES-SCLC combines REQORSA with Genentech's Tecentriq; Phase 2 expansion to enroll ~50 patients.
- Interim analysis planned after 25th patient reaches 18 weeks; enrollment completion expected first half 2026.
- Acclaim-3 has FDA Fast Track and Orphan Drug designations.

## SEC filing metadata
- accession: 0001437749-25-035514
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925035514/0001437749-25-035514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925035514/gnpx20251116_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-035514
- JSON: https://secwatch.observer/filing/0001437749-25-035514.json
- Plain text: https://secwatch.observer/filing/0001437749-25-035514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.